Market Place
Sourcing Support
AceLink Presents Results for AL01211 in Fabry Disease Patients
07 Feb 2025 //
BUSINESSWIRE
AceLink Announces Publication of Phase 1 Trial Data Evaluating AL01211
26 Feb 2024 //
BUSINESSWIRE
AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211
31 Oct 2023 //
BUSINESSWIRE
AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease
10 Aug 2023 //
BUSINESSWIRE
AceLink Therapeutics approved to begin Fabry disease drug trial
22 Jun 2023 //
CLINICAL TRIALS ARENA
AceLink Receives FDA Clearance to Initiate a Ph2 Study of AL1211
21 Jun 2023 //
BUSINESSWIRE
AceLink Therapeutics to Present at World Orphan Drug Congress USA
17 May 2023 //
BUSINESSWIRE
AceLink Presents Preclinical Data on AL00804 at WORLD Symposium
23 Feb 2023 //
BUSINESSWIRE
AceLink Presents PI Study of AL01211 to Treat Fabry Disease at WORLD Symposium
23 Feb 2023 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.